Citius Pharmaceuticals (CTXR) Stock Rating Lowered by Zacks Investment Research

Citius Pharmaceuticals Inc logo Zacks Investment Research cut shares of Citius Pharmaceuticals (NASDAQ:CTXR) from a hold rating to a sell rating in a research report report published on Monday.

According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. “

Get Citius Pharmaceuticals alerts:

Other research analysts also recently issued reports about the stock. HC Wainwright reissued a buy rating and set a $3.00 price target on shares of Citius Pharmaceuticals in a research note on Thursday, February 7th. ValuEngine downgraded shares of Citius Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, December 21st.

CTXR stock opened at $1.52 on Monday. Citius Pharmaceuticals has a one year low of $0.86 and a one year high of $3.15.

A hedge fund recently bought a new stake in Citius Pharmaceuticals stock. Renaissance Technologies LLC purchased a new position in shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 58,333 shares of the company’s stock, valued at approximately $100,000. Renaissance Technologies LLC owned approximately 0.36% of Citius Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 5.01% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Citius Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Citius Pharmaceuticals and related companies with’s FREE daily email newsletter .

Click Here to Continue...